Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in treatment-resistant depression
2024-518654-16-01Phase 2Authorised
- Sponsor
- LKH Graz II
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by LKH Graz II. Primary endpoint: Severity of depression (BDI-II) at 1 week after 4 weeks of psilocybin administration. Planned start Jan 2025; status: authorised.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-518654-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518654-16-01.